BACKGROUND: To determine whether pulmonary metastasectomy or the addition of ifosfamide/dacarbazine to a doxorubicin-containing regimen offers a survival benefit to adult patients with metastatic leiomyosarcoma. PATIENTS AND METHODS: We retrospectively collected data from 147 patients treated with a doxorubicin-containing regimen from 1998 to 2008. RESULTS: Progression-free survival (PFS) was 6.5 months (range 1-141 months). We did not identify an independent prognostic factor for PFS. Planned dose of doxorubicin was the sole parameter improving PFS [hazard ratio (HR) = 0.13, P = 0.023]. Overall survival (OS) was 17 months (range 1-115 months). The sole identified prognostic factor for OS was the interval between initial diagnosis and metastatic relapse. After adjustment to this prognostic factor, metastasectomy improved OS (HR = 0.52, P = 0.012) and the addition of ifosfamide seemed to worsen OS (HR = 1.42, P = 0.028). CONCLUSION: In our analysis, combined regimens did not improve the outcome. Maintenance of the doxorubicin dose was associated with improved PFS. Metastasectomy favorably influenced OS.
BACKGROUND: To determine whether pulmonary metastasectomy or the addition of ifosfamide/dacarbazine to a doxorubicin-containing regimen offers a survival benefit to adult patients with metastatic leiomyosarcoma. PATIENTS AND METHODS: We retrospectively collected data from 147 patients treated with a doxorubicin-containing regimen from 1998 to 2008. RESULTS: Progression-free survival (PFS) was 6.5 months (range 1-141 months). We did not identify an independent prognostic factor for PFS. Planned dose of doxorubicin was the sole parameter improving PFS [hazard ratio (HR) = 0.13, P = 0.023]. Overall survival (OS) was 17 months (range 1-115 months). The sole identified prognostic factor for OS was the interval between initial diagnosis and metastatic relapse. After adjustment to this prognostic factor, metastasectomy improved OS (HR = 0.52, P = 0.012) and the addition of ifosfamide seemed to worsen OS (HR = 1.42, P = 0.028). CONCLUSION: In our analysis, combined regimens did not improve the outcome. Maintenance of the doxorubicin dose was associated with improved PFS. Metastasectomy favorably influenced OS.
Authors: Christina L Roland; Genevieve M Boland; Elizabeth G Demicco; Kristelle Lusby; Davis Ingram; Caitlin D May; Christine M Kivlin; Kelsey Watson; Ghadah A Al Sannaa; Wei-Lien Wang; Vinod Ravi; Raphael E Pollock; Dina Lev; Janice N Cormier; Kelly K Hunt; Barry W Feig; Alexander J Lazar; Keila E Torres Journal: JAMA Surg Date: 2016-04 Impact factor: 14.766
Authors: Mercy Varghese; Oyvind Bruland; Anne Marit Wiedswang; Ingvild Lobmaier; Bård Røsok; Robert S Benjamin; Kirsten Sundby Hall Journal: Clin Sarcoma Res Date: 2016-02-24
Authors: Marie Kostine; Inge H Briaire-de Bruijn; Arjen H G Cleven; Carly Vervat; Willem E Corver; Marco W Schilham; Els Van Beelen; Hester van Boven; Rick L Haas; Antoine Italiano; Anne-Marie Cleton-Jansen; Judith V M G Bovée Journal: Oncoimmunology Date: 2017-10-26 Impact factor: 8.110
Authors: A N Shoushtari; J Landa; D Kuk; A Sanchez; B Lala; N Schmidt; C Okoli; P Chi; M A Dickson; M M Gounder; M L Keohan; A M Crago; W D Tap; S P D'Angelo Journal: Sarcoma Date: 2016-05-29